The U.S. Supreme Court has issued a temporary order reinstating the ability of healthcare providers to prescribe and ship mifepristone, a key medication for non-surgical abortions, via mail. This interim ruling pauses a lower court’s decision that had banned remote prescribing, keeping access open until at least May 11. The move sets the stage for the nation’s highest court to ultimately decide whether federal regulations allowing telehealth prescriptions for the drug can stand.
The Legal Battle Over Telehealth Prescriptions
The conflict stems from a lawsuit filed in 2025 by the state of Louisiana against the U.S. Food and Drug Administration (FDA). The state challenged a Biden administration policy that permitted telehealth practitioners to prescribe mifepristone to patients anywhere in the country, including those residing in states with strict abortion bans.
Initially, a lower court paused the lawsuit while the FDA conducted a review of mifepristone regulations. However, Louisiana appealed that decision. On May 1, an appeals court ruled to halt telehealth prescriptions pending the completion of the FDA’s review, which is due for a status update by October 7.
The Supreme Court’s intervention came after emergency requests from Danco and GenBioPro, the manufacturers of mifepristone. Justice Samuel Alito issued the stay, allowing healthcare professionals to continue offering the drug through telemedicine for the time being. He has ordered the parties involved to file legal briefs by 5 P.M. EDT on Thursday, after which the Court will determine its next steps.
Safety Data and Political Scrutiny
At the heart of this legal dispute is a clash between established medical consensus and political skepticism regarding the drug’s safety. The FDA has approved mifepristone for use in early-term pregnancies since 2000 (up to 49 days gestation) and expanded that approval to 70 days in 2016. The agency maintains that the drug is safe when used according to medical guidelines.
Data supports this stance. According to the FDA, there have been only 36 reported deaths among individuals who took mifepristone since its initial approval in 2000. Notably, two of these cases involved ectopic pregnancies, a condition for which the drug is not advised. The FDA emphasizes that no causal link has been definitively established between the drug and these adverse events, noting that such reports are common for all approved prescription medications.
Despite this record, Health and Human Services Secretary Robert F. Kennedy Jr. has ordered the current review, expressing doubt about the drug’s safety based on a paper from a conservative think tank. In response, an independent study released earlier this year analyzed thousands of pages of FDA documents and concluded that the agency’s approval process was cautious and firmly grounded in scientific principles.
Medical Community Reacts
The legal back-and-forth has drawn sharp criticism from medical experts and patient advocates, who argue that the litigation creates unnecessary confusion and risk for patients.
“This entire case and process is all unnecessary, because mifepristone has long, long, long, long been proven to be safe and effective in helping people manage their medication abortions,” said Aishat Olatunde, a board-certified obstetrician-gynecologist.
Legal advocates also highlighted the precarious nature of the current situation. Julia Kaye, senior staff attorney for the Reproductive Freedom Project of the American Civil Liberties Union (ACLU), stated that while the stay is a short-term victory, it does not resolve the underlying uncertainty. “No one can rest easy when our ability to get this safe, effective medication for abortion and miscarriage care still hangs in the balance,” Kaye said, urging the Supreme Court to end what she termed a “baseless attack” on reproductive freedom.
Molly Meegan, chief legal officer at the American College of Obstetricians & Gynecologists, echoed these concerns, noting that the ongoing litigation leaves both patients and clinicians confused about medication availability. She urged the Court to rely on science and evidence, which she said overwhelmingly support removing in-person dispensing requirements.
Looking Ahead
For doctors like Dr. Olatunde, the primary concern is the impact on patients who face mixed information and sudden changes in access. “I know it can be frustrating to have the back and forth between the courts, because, ultimately, who suffers are patients,” she said.
The hope among medical professionals is that the Supreme Court will recognize the reality that patients will seek care regardless of legal hurdles, and that the final ruling will prioritize medical access. The upcoming legal briefs will be critical in determining whether mifepristone can continue to be dispensed by mail and through pharmacies as a standard part of reproductive healthcare.
The Supreme Court’s final decision will not only determine the future of telehealth prescriptions for mifepristone but also signal how the judiciary balances federal drug regulations against state-level abortion restrictions.
